MedTrace Logo

Intranasal Lorazepam Versus Intramuscular Paraldehyde in Paediatric Convulsions

NCT00116064 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 156

Last updated 2006-07-21

No results posted yet for this study

Summary

The purpose of this study is to evaluate intranasal lorazepam in paediatric status epilepticus. This is a potentially, more effective, safer and cheaper treatment for a common paediatric medical emergency compared to our present first line therapy intramuscular paraldehyde.

Conditions

  • Status Epilepticus
  • Convulsions

Interventions

DRUG

intranasal lorazepam

DRUG

intramuscular paraldehyde

Sponsors & Collaborators

  • Kamuzu University of Health Sciences

    lead OTHER

Principal Investigators

  • Elizabeth Molyneux, MRCPCH FFAEM · Kamuzu University of Health Sciences

  • Shafique Ahmad, MRCPCH FFAEM · Kamuzu University of Health Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
2 Months
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-07-31
Completion
2005-06-30

Countries

  • Malawi

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00116064 on ClinicalTrials.gov